Gemeinsame Stellungnahme der DGHO und DGVS zur Nutzenbewertung von Nivolumab in Kombination mit Chemotherapie (Adenokarzinom von Ösophagus, gastroösophagealem Übergang und Magen)

• Literatur

• 1 https://www.gekid.de/wp-content/uploads/2022/01/krebs_in_deutschland_2021.pdf ; Zugriff 4. März 2022
• 2 S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösopha- gus, Oktober 2018. https://www.awmf.org/leitlinien/detail/ll/021-023OL.html
• 3 Stahl M. et al. Ösophaguskarzinom, Onkopedia, April 2021. https://www.onkopedia.com/de/onkopedia/guidelines/oesophaguskarzinom/@@guideline/html/index.html
• 4 Interdisziplinäre S3-Leitlinie: Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs. Registernummer 032-009OL, August 2019.
• 5 https://www.awmf.org/uploads/tx_szleitlinien/032-009l_S3_Magenkarzinom_Diagnostik_Therapie_Adenokarzinome_oesophagogastraler_Uebergang_2019-12.pdf
• 6 Lordick F. et al. Magenkarzinom. Leitlinien von DGHO, OeGHO, SGMO und SGH+SSH, Status März 2021. https://www.onkopedia.com/de/onkopedia/guidelines/oesophaguskarzinom/@@guideline/html/index.html
• 7 Glimelius B, Ekstrom K, Hoffman K. et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168
• 8 Wagner AD, Unverzagt S, Grothe W. et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2017;
• 9 Al-Batran SE, Hartmann JT, Probst S. et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26: 1435-1442
• 10 Cunningham D, Starling N, Rao S. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46
• 11 Okines AFC, Norman AR, McCloud P. et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009; 20: 1529-1534
• 12 Dank M, Zaluski J, Barone C. et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adecarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19: 1450-1457
• 13 Guimbaud R, Louvet C, Ries P. et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol 2014; 32: 3520-3526
• 14 Sun JM, Shen L, Shah MA. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021; 398: 759-771
• 15 Janjigian YY, Shitara K, Möhler M. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (Check- Mate 649): a randomised, open-label, phase 3 trial. Lancet 2021; 398: 27-40
• 16 Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. https://oncologypro.esmo.org/meeting-resources/esmo-congress/nivolumab-nivo-plus-chemotherapy-chemo-or-ipilimumab-ipi-vs-chemo-as-first-line-1l-treatment-for-advanced-gastric-cancer-gastroesophageal-j
• 17 Cherny NI, Sullivan R, Dafni U. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573
• 18 Cherny NI, Dafni U, Bogaerts J. et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol 2017; 28: 2340-2366